QP Pharmachem asked to stop manufacturing after samples found to be of non-standard quality: Govt
New Delhi: A Punjab-based drugmaker was asked to stop all manufacturing activities after samples collected from its premises, following an alert by the WHO, were found to be "not of standard quality", the Lok Sabha was informed on Friday. Minister of State for Health Bharati Pravin Pawar, in a written reply in the Lower House of Parliament, said the World Health Organization (WHO) issued a medical product alert for a batch of India-made Guaifenesin syrup in the Marshall Islands and the Federated States of Micronesia.
Read also: Manufacturing licences of QP Pharmachem, 2 others suspended
Medical Dialogues team had reported that the Drug Controller General of India (DCGI) had notified all drug manufacturers' associations and exporters not to submit the same batch of cough syrup to more than one laboratory at a time, as this practice is highly objectionable and not acceptable from a regulatory standpoint.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.